Key facts
- Five EU countries (Belgium, Netherlands, Luxembourg, Austria, Ireland) are advocating for a unified European approach to drug pricing.
- The U.S. administration is pressuring European nations to increase medicine prices, with Germany's prices being around three times lower than in the U.S.
- U.S. embassies are negotiating bilateral drug pricing deals, with the U.K. reportedly paying more for medicines to avoid tariffs.
- Pharmaceutical companies like Pfizer, Eli Lilly, and Boehringer Ingelheim have expressed concerns or stalled investments in Germany due to its pricing policies.
- EU ministers are set to discuss drug pricing pressures, though national governments retain competence over health policy.
Five European nations have called for a unified approach to drug pricing in the face of increasing pressure from the U.S. and pharmaceutical companies. Belgium, the Netherlands, Luxembourg, Austria, and Ireland, members of the Beneluxa initiative, stated that collaboration is necessary to address shared challenges and warned against uncoordinated national responses.
The U.S. administration, under President Donald Trump, is reportedly demanding that European countries pay higher prices for medicines, which are currently around three times lower in Germany than in the United States. U.S. embassies are actively negotiating bilateral drug pricing deals, with the U.K. having agreed to pay more for its medicines in exchange for avoiding U.S. tariffs.
This pressure comes as Germany is undergoing reforms to its healthcare system, including changes to drug pricing rules. Pharmaceutical giants like Pfizer, Eli Lilly, and Boehringer Ingelheim have expressed concerns, with Pfizer CEO Albert Bourla reportedly discussing the matter with German Chancellor Friedrich Merz. Eli Lilly and Boehringer Ingelheim have already paused planned investments in Germany.
EU ministers are scheduled to meet in Luxembourg to discuss these pricing pressures, though health policy remains largely a national competence. Sweden has also organized a separate meeting for ministers to discuss coordinated responses to geopolitical challenges in the pharmaceutical sector.
Meanwhile, the European Commission has proposed extending patent rights for certain biotech medicines, a move that public payers and patient groups fear will increase medicine costs. The generics industry suggests accelerating the adoption of off-patent alternatives could save the EU significant funds.